From FDA labels and ClinicalTrials.gov

Do GLP-1s reduce drinking?

Last updated

If your prescriber prescribes one: the lowest self-pay GLP-1 prices now

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest FDA-approved, starting dose

    LillyDirect (Eli Lilly)

    from $149/mo

  • Lowest FDA-approved injection, starting dose

    NovoCare (Novo Nordisk)

    $199/fill initially

No current GLP-1 label lists alcohol use as an approved use, so prescribing one for it would be off-label. Hendershot et al. (Semaglutide): A 9-week Phase 2 trial of low doses in 48 people not seeking treatment. Semaglutide reduced how much alcohol they drank in a lab task, the main measure, and also drinks on drinking days and craving, but not average drinks per day or the number of drinking days. The authors call for larger trials. JAMA Psychiatry, 2025 (pubmed.ncbi.nlm.nih.gov/39937469). ClinicalTrials.gov lists 23 trials of these medicines on it: 2 with posted results and 8 recruiting now.

Read from the registry and PubMed every day. The newest update here is Nov 16, 2026.

Published results

What the largest trials on alcohol use found

Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.

Hendershot et al.

Semaglutide · 48 people · Mixed · Placebo-controlled randomized trial

A 9-week Phase 2 trial of low doses in 48 people not seeking treatment. Semaglutide reduced how much alcohol they drank in a lab task, the main measure, and also drinks on drinking days and craving, but not average drinks per day or the number of drinking days. The authors call for larger trials.

JAMA Psychiatry, 2025 (pubmed.ncbi.nlm.nih.gov/39937469)

Klausen et al.

Exenatide · 127 people · No clear benefit · Placebo-controlled randomized trial

Exenatide did not significantly reduce heavy drinking days against placebo.

JCI Insight, 2022 (pubmed.ncbi.nlm.nih.gov/36066977)

The registry

Trials on alcohol use, by medicine

A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.

MedicineTrialsPosted resultsRecruiting
Semaglutide1213
Tirzepatide605
Exenatide310
Mazdutide100
Pemvidutide100
Posted results

What trials on alcohol use reported

Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.

TrialMedicinePhasePeopleResult
NCT05520775Semaglutide for Alcohol Use DisorderSemaglutidePhase 248Change in Alcohol Consumed (grams), Baseline (Week 0) to post-medication (Week 8). Semaglutide: -32.72; Sham/Placebo: -6.95.
NCT03645408The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy DrinkersExenatidePhase 18Alcohol Consumption (standard drink units (SDUs)), 2 hours. Exenatide Injection: 0.93; Sham Injection (Placebo): 2.78.
Recruiting now

Trials on alcohol use taking people now

The registry page names each site and who can enroll. Ask your clinician before joining one.

TrialMedicinePhaseExpected to finish
Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE) (clinicaltrials.gov/study/NCT07218354)SemaglutidePhase 3Mar 30, 2030
Tirzepatide in MetALD (clinicaltrials.gov/study/NCT07046819)TirzepatidePhase 2Jul 30, 2027
Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder (clinicaltrials.gov/study/NCT06939088)TirzepatidePhase 2Dec 31, 2028
Tirzepatide for Alcohol Use Disorder (clinicaltrials.gov/study/NCT06994338)TirzepatidePhase 2Aug 31, 2026
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide (clinicaltrials.gov/study/NCT07040592)SemaglutidePhase 2Jun 30, 2027
Study of Tirzepatide for Recovery and Alcohol Use Management (clinicaltrials.gov/study/NCT06727331)TirzepatidePhase 2Jul 1, 2027
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD) (clinicaltrials.gov/study/NCT07559500)TirzepatidePhase 1Dec 31, 2031
Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes (clinicaltrials.gov/study/NCT07772960)SemaglutidePhase 1Oct 31, 2031
From PubMed

Newest papers on GLP-1s and alcohol use

  • Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial (pubmed.ncbi.nlm.nih.gov/42522065)

    Randomized trial · Am J Psychiatry · Jul 29, 2026 · Schacht JP et al. · cited by 7

  • Glucagon-like Peptide-1 Receptor Agonists and Alcohol Use Outcomes: A Systematic Review of Clinical Evidence (pubmed.ncbi.nlm.nih.gov/42355949)

    Systematic review · J Clin Med · Jun 19, 2026 · Altami IK et al.

  • Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial (pubmed.ncbi.nlm.nih.gov/42070571)

    Randomized trial · Lancet · May 1, 2026 · Klausen MK et al. · cited by 35

  • Repurposing GLP-1 receptor agonists for alcohol use disorder: a systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/41508124)

    Meta-analysis · Diabetol Metab Syndr · Jan 8, 2026 · Nasrollahizadeh A et al. · cited by 4

  • Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/41324012)

    Meta-analysis · EClinicalMedicine · Nov 14, 2025 · Eshraghi R et al. · cited by 3

  • GLP-1 receptor agonists and alcohol use disorder: a systematic review (pubmed.ncbi.nlm.nih.gov/41273789)

    Systematic review · Alcohol Alcohol · Nov 1, 2025 · Patel S et al.

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Updated automatically

What changed in trials on alcohol use

  • TrialSemaglutide study now recruiting (was not yet recruiting): Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes (clinicaltrials.gov/study/NCT07772960)

Written from each source's own record as it changes. Every change on GLPcompare

Questions

GLP-1s and alcohol use: common questions

What did the largest trial on alcohol use find?

Hendershot et al. (Semaglutide, 48 people): A 9-week Phase 2 trial of low doses in 48 people not seeking treatment. Semaglutide reduced how much alcohol they drank in a lab task, the main measure, and also drinks on drinking days and craving, but not average drinks per day or the number of drinking days. The authors call for larger trials.

Is any GLP-1 FDA approved for alcohol use?

Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.

Which GLP-1 has been studied most for alcohol use?

Semaglutide, with 12 registered trials on it, then Tirzepatide with 6. More trials do not mean better results: read what each posted.

Can I join a trial of a GLP-1 for alcohol use?

8 trials are recruiting on ClinicalTrials.gov now, listed on this page with their registry pages, which name each site and who can enroll.

Other conditions

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.